Core Viewpoint - The article discusses the complex interactions between cancer cells and the tumor microenvironment (TME), emphasizing the potential of targeted cancer immunotherapies to disrupt immunosuppressive interactions, although many therapies show limited durability due to a lack of understanding of these interactions [2][3]. Group 1: Research Findings - A study published by a team from the University of Chicago reveals that tumor-initiating stem cells (tSC) regulate the plasticity of neutrophils through metabolic reprogramming, creating a protective niche that allows them to survive cancer immunotherapy, leading to cancer recurrence [4]. - The research indicates that targeting the SOX2-FADS1-PGE2 signaling axis could serve as a novel combination therapy strategy to prevent immunotherapy resistance and tumor recurrence [4]. Group 2: Mechanisms of Immune Evasion - The study highlights the heterogeneity of tumor-associated neutrophils (TAN) and how different states of TAN arise and evolve, impacting the effectiveness of cancer immunotherapy [8]. - It was found that anti-PDL1 + CD40 agonist immunotherapy can induce TAN to regain anti-tumor activity in squamous cell carcinoma (SCC), while TAN at the tumor-stroma interface maintain their immunosuppressive state [8]. Group 3: Key Pathways and Implications - The SOX2 high-expressing tSCs enhance PGE2 signaling in TAN, which may disrupt interferon responses and inhibit the anti-tumor functions of TAN [9]. - Specific knockout of PGE2 receptors in neutrophils or using COX-2 inhibitors to block PGE2 synthesis can effectively restore the anti-tumor functions of neutrophils, enhancing the efficacy of immunotherapy and significantly reducing tumor recurrence rates [9]. Group 4: Overall Conclusions - The research explores how effective immunotherapies influence the plasticity of TAN, revealing how tSCs evade TAN-mediated anti-tumor immunity, allowing them to survive cancer immunotherapy and promote recurrence [12].

Core Viewpoint - Cancer immunotherapy has revolutionized cancer treatment by activating the immune system to attack tumors, but many patients still face tumor recurrence, with underlying mechanisms not fully understood [1][4]. Group 1: Tumor-Initiating Stem Cells (tSC) - Tumor-initiating stem cells (tSC) are considered a key cell population responsible for tumor recurrence, yet their role in regulating the immune microenvironment remains largely unknown [1][5]. - Recent research indicates that tSC can survive during strong anti-tumor immune responses induced by immunotherapy, contributing to cancer recurrence post-treatment [5][10]. Group 2: Neutrophils in Tumor Microenvironment - Neutrophils, as one of the most abundant immune cells in the tumor microenvironment (TME), have a close relationship with the effectiveness of immunotherapy [1][4]. - Tumor-associated neutrophils (TAN) have been traditionally viewed as having immunosuppressive roles, but recent studies suggest they can enhance anti-tumor immune responses by presenting new antigens through MHCII molecules [1][6]. Group 3: Research Findings - A study published in Cancer Cell reveals that tSC regulate the plasticity of neutrophils through metabolic reprogramming, creating a protective niche that allows them to survive during cancer immunotherapy, leading to recurrence [2][10]. - The study identifies a specific signaling axis (SOX2-FADS1-PGE2) that could serve as a novel combination therapy strategy to prevent immunotherapy resistance and tumor recurrence [2][10]. Group 4: Implications of Findings - The research highlights the dynamic interactions between tSC and TAN, showing that effective immunotherapy can induce different responses in various TAN subpopulations [8][10]. - The findings suggest that targeting the PGE2 signaling pathway can restore the anti-tumor functions of neutrophils, enhancing the effectiveness of immunotherapy and significantly reducing tumor recurrence rates [7][12].